Navigation Links
USC researchers identify novel approach for suppressing prostate cancer development
Date:11/24/2008

Los Angeles, Calif. Nov. 24, 2008Researchers at the University of Southern California (USC) have found that inactivating a specific biomarker for aggressive prostate cancer blocks the development of prostate cancer in animal models.

Researchers say the upcoming study in the Proceedings of the National Academy of Sciencesnow available onlinemay lead to a novel cancer therapy for humans.

"This research has far-reaching implications in a wide range for human cancers," says Amy Lee, Ph.D., the study's principal investigator and the associate director for basic research and holder of the Freeman Cosmetics Chair at the USC/Norris Comprehensive Cancer Center, and professor of biochemistry and molecular biology at the Keck School of Medicine of USC. "It is a breakthrough study."

Prostate cancer is the most common cancer in men and develops through successive stages. The glucose-regulated protein GRP78 has been identified as a crucial entity in the development of prostate cancer by promoting cancer cell proliferation, mediating oncogenic signaling and protecting cancer cells against cell death resulting from the stress of tumor development, Lee explains. By suppressing GRP78 expression or activity, the USC researchers found that they could block prostate cancer activation and development resulting from the loss of PTEN, a powerful tumor suppressor gene for a number of human cancers.

Researchers spent more than three years monitoring prostate cancer development in animal models that had been genetically engineered to have both the GRP78 and PTEN tumor suppressor genes inactivated. The research was conducted by Yong Fu, a Ph.D. candidate at the Keck School of Medicine of USC and the first author on the study, in collaboration with Ph.D candidates Shiuan Wey, Miao Wang, Risheng Ye and Chun-Peng Liao and Pradip Roy-Burman, M.D., professor of pathology, biochemistry and molecular biology at the Keck School.

Future research should test t
'/>"/>

Contact: Meghan Lewit
lewit@usc.edu
323-442-3941
University of Southern California
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Researchers identify new leprosy bacterium
2. UT Southwestern researchers develop new strategy for broad spectrum anti-viral drugs
3. Researchers discover strategy for predicting the immunity of vaccines
4. Ability to quit smoking may depend on ADHD symptoms, Columbia researchers find
5. Researchers ID Suite of Genes in Aging Process
6. Researchers: Ban on fast food TV advertising would reverse childhood obesity trends
7. Brigham and Womens Researchers Partner with Vocantas to use CallAssure in Clinical Research Study
8. Leeds researchers reshape the future of drug discovery
9. UNC researchers find clue to stopping breast-cancer metastasis
10. U of U researchers to use patients own stem cells to treat heart failure
11. Researchers identify toehold for HIVs assault on brain

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)... EDINA,Minn.,Nov.25/PRNewswire-USNewswire/--Whenmo...Butachiropractorcanalsogivepatientsthehelptheyneed...ereyourjaw(mandible)contacts/connectswithyourskull...tedwithTMJdysfunctionarepainwithchewing,clickingor...mTMJdysfunctionincluding:headaches,fatigue,sleepdi...
(Date:11/25/2009)... TORONTO,Nov.25/PRNewswire/-SentinelleMedicalInc.,...ualizationsoftwarelaunchesasuiteofnewleadingedgecl...wareplatformatthisyear,sRadiologicalSocietyofNorth...009(Booth5800,HallA).Theapplicationsleveragetheuni...izedMRIimagingcoilsandsupportmultipleimagingmodali...
(Date:11/25/2009)... SANFRANCISCO,Nov.25/PRNewswire/--TheBayAreaAirQua...nter Spare the Air Alert forThursday...irelogsoranyothersolidfuel,bothindoorsandoutdoors....airqualitytomorrow,"saidJackBroadbent,executiveoff...orespectthehealthoftheirneighborsandfellowcommunit...
(Date:11/25/2009)...ortuitous discovery that grew out of a collaborati...entially offer hope to the nearly 10 million Ameri... , Also known as hardening of the arteries, p...rculatory problem in which narrowed arteries reduc...ered a red flag for vascular disease, heart attack...
(Date:11/25/2009)... Evaluation and treatment clinic... Woodstock (Vocus) November 25, 2009 -- Centeg... vaccines and H1N1 vaccine shots at four Centegra ...er shipment of vaccine has arrived. The clinics ar... and McHenry and will be open as follows: , &n...
Breaking Medicine News(10 mins):Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 3Health News:Winter Spare the Air Alert in Effect for Thursday, November 26, 2009 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 4
...wn to have a genetic predisposition. //This study ... DNA double helix. Collaborated Research is b...de Hospital campus of The Feinstein Institute for ... that vary dramatically in symptoms and severity a...
...greement to deliver a fast, efficient new electron...ve as a win for patients and doctors alike. T...irst organisation to sign up to deliver the new sy...mmittee on Information Technology, Dr Peter Garcia...
...and disappointment on hearing the news about a Lib...ences on five Bulgarian nurses and one Palestinian...reds of children with HIV. George Bush has exp...urses would be fully supported by him. The US ...
...IDF) Diabetes Atlas released early December in Sou...hest in India.// But China overtakes India in the ...T). The Atlas, third in a series that began i... is predicted to increase dramatically over the ne...
...read to many different sites often do not have man...to tolerate the doses of treatment they would need... Hope and St. Jude Children's Research Hospital ma...trate chemotherapeutic drugs predominately at tumo...
... research centre is being planned at the Pune-base...eat diseases//, a general says. "Stem cell ther...edicine. It will be the futuristic treatment repla...e disease and various other diseases can be cured,...
Other Medicine News:Health News:Research on Bipolar Disorder Launched 2Health News:Researchers Find Stem-cell Therapy Effective in Targeting Metastatic Cancer 2Health News:Military College to Set Up Stem Cell Research Centre 2
(Date:11/25/2009)...ire/--Reportlinker.comannouncesthatanewmarketresea...nagement-GlobalTrends ,, http://www.reportli...html ,, Widespreadavailabilityofgenericdrugs,e...rugshaveacceleratedthepaceofgrowthinthepainmanagem...recontinuetoshapedemandforservices,drugsanddevices...
(Date:11/25/2009)...NEY,Nov.25/PRNewswire-FirstCall/--HeartWareInterna...orandprovideroflessinvasive,miniaturizedcirculator...dvancedheartfailure,todayannouncedthatitisschedule...affrayHealthCareConferenceat8:00amESTonWednesday,D...PalaceHotel,December1-2. ,, AlivewebcastoftheCo...
(Date:11/24/2009)...wswire/-- ,, WHAT:RomHoubens,aBelgianmanthought...wasactuallyfullyconsciousandawakeduringthattimeand...oxEyeMaxwasfeaturedinthesegmenttoillustratehowpeop...communication. ,, WHEN:GoodMorningAmerica-- Tue...ch.com ,, WHO:RomHoubenswasanengineeringstu...
Breaking Medicine Technology:Reportlinker Adds Pain Management - Global Trends 2Reportlinker Adds Pain Management - Global Trends 3Reportlinker Adds Pain Management - Global Trends 4Reportlinker Adds Pain Management - Global Trends 5DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 13428 1InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 13428 2InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 13428 3InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 13428 4InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 13428 5InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 13428 6InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 13428 7InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 13428 8InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 13428 9InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 13428 10InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 13428 11InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 13428 12InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 13428 13InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 13428 14InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 13428 15OncoGenex Reports Second Quarter 2009 Financial Results 13426 1OncoGenex Reports Second Quarter 2009 Financial Results 13426 2OncoGenex Reports Second Quarter 2009 Financial Results 13426 3OncoGenex Reports Second Quarter 2009 Financial Results 13426 4OncoGenex Reports Second Quarter 2009 Financial Results 13426 5OncoGenex Reports Second Quarter 2009 Financial Results 13426 6OncoGenex Reports Second Quarter 2009 Financial Results 13426 7Vectibix 28R 29 in Combination With Chemotherapy Significantly Improved Progression Free Survival in First Line Metastatic Colorectal Cancer 4834 1Vectibix 28R 29 in Combination With Chemotherapy Significantly Improved Progression Free Survival in First Line Metastatic Colorectal Cancer 4834 2Vectibix 28R 29 in Combination With Chemotherapy Significantly Improved Progression Free Survival in First Line Metastatic Colorectal Cancer 4834 3Vectibix 28R 29 in Combination With Chemotherapy Significantly Improved Progression Free Survival in First Line Metastatic Colorectal Cancer 4834 4Vectibix 28R 29 in Combination With Chemotherapy Significantly Improved Progression Free Survival in First Line Metastatic Colorectal Cancer 4834 5Vectibix 28R 29 in Combination With Chemotherapy Significantly Improved Progression Free Survival in First Line Metastatic Colorectal Cancer 4834 6Vectibix 28R 29 in Combination With Chemotherapy Significantly Improved Progression Free Survival in First Line Metastatic Colorectal Cancer 4834 7Vectibix 28R 29 in Combination With Chemotherapy Significantly Improved Progression Free Survival in First Line Metastatic Colorectal Cancer 4834 8
OCUFLOX® 5 mL
ALPHAGAN® 5 mL
ACULAR® 5 mL
ACULAR® 10 mL
Medicine Products: